Burgents, Joseph

Olaparib for Metastatic Castration-Resistant Prostate Cancer

de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 2,323

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 792

The Inflammasome Component Nlrp3 Impairs Antitumor Vaccine by Enhancing the Accumulation of Tumor-Associated Myeloid-Derived Suppressor Cells

van Deventer, H. W., Burgents, J. E., Wu, Q. P., Woodford, R.-M. T., Brickey, W. J., Allen, I. C., McElvania-Tekippe, E., Serody, J. S., & Ting, J. P.-Y. (2010) · Cancer Research

Immunotherapy and Immune ResponsesInflammasome and immune disorders

Cited by 172

Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer

Shore, N., Ionescu-Ittu, R., Yang, L., Laliberté, F., Mahendran, M., Lejeune, D., Yu, L., Burgents, J., Duh, M. S., & Ghate, S. R. (2021) · Future Oncology

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 36